Klinikum der Universität München

Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor (2025) Wegert J, Appenzeller S, Treger TD, Streitenberger H, Ziegler B, Bausenwein S, Vokuhl C, et al. Journal article PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma (2025) Zeremski V, Haage TR, Witte HM, Adolph L, Beer SA, Behre G, Jacobs B, et al. Journal article Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases (2025) Mravinacová S, Bergström S, Olofsson J, de San José NG, Anderl-Straub S, Diehl-Schmid J, Fassbender K, et al. Journal article Use of sedative drugs in specialist palliative care (iSedPall): a multi-modal intervention pilot study protocol (2025) Ostgathe C, Bausewein C, Schildmann E, Bazata J, Heckel M, Kauzner S, Klein C, et al. Journal article Correction to: Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals (BMC Medicine, (2024), 22, 1, (346), 10.1186/s12916-024-03548-z) (2025) Liwinski T, Auer MK, Schröder J, Pieknik I, Casar C, Schwinge D, Henze L, et al. Journal article, Erratum TGFα controls checkpoints in CNS resident and infiltrating immune cells to promote resolution of inflammation (2025) Lößlein L, Linnerbauer M, Zuber F, Tsaktanis T, Vandrey O, Peter A, Panier F, et al. Journal article Correction: "Is this sedation?” – a Group Delphi process to define cut-off doses and dosing intervals for potentially sedating drugs in palliative care (BMC Palliative Care, (2025), 24, 1, (159), 10.1186/s12904-025-01781-8) (2025) Krauss SH, Rémi C, Bausewein C, Bazata J, Grebe A, Ostgathe C, Schildmann J, Schildmann E Journal article, Erratum Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG (2025) Leven AS, Peters T, Rajcsanyi LS, Weichenthal M, Mohr P, Meier F, von Wasielewski I, et al. Journal article Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer (2025) Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, et al. Journal article Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease – Design and rationale of the randomized COMPLETE-NSTEMI trial (2025) Feistritzer HJ, Jobs A, Zeymer U, Schneider S, Lauten P, Ferenc M, Weferling M, et al. Journal article